Results 241 to 250 of about 271,092 (363)

Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas

open access: yesJournal of Surgical Oncology, 2017
K. Nastos   +6 more
semanticscholar   +1 more source

Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers

open access: yesJournal of Surgical Oncology, Volume 132, Issue 5, Page 789-809, October 2025.
ABSTRACT Peritoneal malignancy often indicates disruptions in multiple physiological systems resulting from widespread cancer. The heterogenous origin and dynamic nature of peritoneal cancer make it difficult to treat with standard approaches that fit into guidelines.
Ada I. Ozcan   +4 more
wiley   +1 more source

Highlight selection of radiochemistry and radiopharmacy developments by editorial board. [PDF]

open access: yesEJNMMI Radiopharm Chem
Toyohara J   +17 more
europepmc   +1 more source

The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances

open access: yesMedComm, Volume 6, Issue 10, October 2025.
Immunotherapy, serving as a crucial breakthrough of precision medicine in the field of cancer treatment, among which immune checkpoint inhibitors (ICIs) have witnessed the most extensive application. This review systematically investigates the challenges, advancements, and future directions of ICIs in tumor treatment.
Hengyi Chen   +3 more
wiley   +1 more source

Understanding time–activity curve and time‐integrated activity variations in radiopharmaceutical therapy challenge: Experience and results

open access: yesMedical Physics, Volume 52, Issue 10, October 2025.
Abstract Background The process of determining/calculating the time–activity curve (TAC) for radiopharmaceutical therapy (RPT) is generally heavily dependent on user‐ and site‐dependent steps (e.g., the number and schedule of measurement points to be used, selection of the fit function), each having a notable effect on the determination of the time ...
Oleksandra V. Ivashchenko   +9 more
wiley   +1 more source

Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects. [PDF]

open access: yesCancers (Basel)
Nawar MF   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy